Back to search

Peptide record

TPDB91535

NK-11 NK11 Antibacterial Anticancer Antifungal Toxicity standard
11 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB91535
NK-11 NK11
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF dbAMP
standard
No
A 11-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, ACP740 _ACP240, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
KISKRILTGKK-NH2
Physicochemical Analysis
C57H110N18O14
ANDCEQHMFPWYV
K
1271.61
11.80
5
0
3
+5
3.87
-0.836
106.36
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
0
0.00
2
Residue Composition
number
0
A
1
R
0
N
0
D
0
C
0
E
0
Q
1
G
0
H
2
I
1
L
4
K
0
M
0
F
0
P
1
S
1
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 2 L: 1 K: 4 M: 0 F: 0 P: 0 S: 1 T: 1 W: 0 Y: 0 V: 0
Chemical Descriptors
11
C57H110N18O14
1271.61
11.80
+5
3.87
-0.836
Amidation
L
Linear
Free
Antimicrobial Anticancer
Synthetic peptide NK2 derived inactive control peptide
Evidence Records 8 records
Evidence 1 Activity

Activity

IC50
IC50 >>100 µM
Anticancer
>100 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
30-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 >>100 µM
Anticancer
>100 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
2-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 3 Activity

Activity

IC50
IC50 >>100 µM
Anticancer
>100 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
4-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 4 Activity

Activity

IC50
IC50 >>100 µM
Anticancer
>100 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 5 Activity

Activity

IC-50 >> 100 µM
Anticancer

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
4-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 6 Activity

Activity

IC-50>> 100 µM
Anticancer

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
30-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 7 Activity

Activity

IC-50 >> 100 µM
Anticancer

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
2-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 8 Activity

Activity

IC50
IC50 >> 100 µM
Anticancer
>100 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013